Rationale for Combining Atezolizumab/Bevacizumab in mRCC

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma in the IMmotion151trial.

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab (Tecentriq) and bevacizumab (Avastin) for patients with metastatic renal cell carcinoma (mRCC) in the IMmotion151trial.

Both of these agents have proven to be active as monotherapies, and as such, it seemed rational to combine them. Additionally, VEGF has immune-suppressive effects, including promoting myeloid-derived suppressor cells, regulatory T cells, etc. By suppressing VEGF, the microenvironment is more favorable for the immunotherapy to act.